{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T10:13:39Z","timestamp":1777630419599,"version":"3.51.4"},"reference-count":24,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.amjmed.2018.08.011","type":"journal-article","created":{"date-parts":[[2018,8,24]],"date-time":"2018-08-24T03:00:20Z","timestamp":1535079620000},"page":"161-167","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Atypical Hemolytic Uremic Syndrome: Beyond Hemolysis and Uremia"],"prefix":"10.1016","volume":"132","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4480-0240","authenticated-orcid":false,"given":"Han-Mou","family":"Tsai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9464","key":"10.1016\/j.amjmed.2018.08.011_bib0001","first-page":"1073","article-title":"Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome","volume":"365","author":"Tarr","year":"2005","journal-title":"Lancet."},{"issue":"3","key":"10.1016\/j.amjmed.2018.08.011_bib0002","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","article-title":"Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \"Kidney Disease: Improving Global Outcomes\" (KDIGO) Controversies Conference","volume":"91","author":"Goodship","year":"2017","journal-title":"Kidney Int."},{"key":"10.1016\/j.amjmed.2018.08.011_bib0003","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1556\/EuJMI.2.2012.2.2","article-title":"The complement system: history, pathways, cascade and inhibitors","volume":"2","author":"Nesargikar","year":"2012","journal-title":"Eur J Microbiol Immunol."},{"issue":"4","key":"10.1016\/j.amjmed.2018.08.011_bib0004","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.tmrv.2014.08.004","article-title":"A mechanistic approach to the diagnosis and management of atypical hemolytic uremic syndrome","volume":"28","author":"Tsai","year":"2014","journal-title":"Transfus Med Rev."},{"issue":"5","key":"10.1016\/j.amjmed.2018.08.011_bib0005","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1586\/17474086.2014.953926","article-title":"Complement in paroxysmal nocturnal hemoglobinuria: exploiting our current knowledge to improve the treatment landscape","volume":"7","author":"Mastellos","year":"2014","journal-title":"Expert Rev Hematol."},{"issue":"1-2","key":"10.1016\/j.amjmed.2018.08.011_bib0006","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jim.2010.12.020","article-title":"Alternative complement pathway assessment in patients with atypical HUS","volume":"365","author":"Roumenina","year":"2011","journal-title":"J Immunol Methods."},{"issue":"23","key":"10.1016\/j.amjmed.2018.08.011_bib0007","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med."},{"issue":"20","key":"10.1016\/j.amjmed.2018.08.011_bib0008","doi-asserted-by":"crossref","first-page":"4060","DOI":"10.1182\/blood-2010-07-271445","article-title":"How I treat patients with thrombotic thrombocytopenic purpura: 2010","volume":"116","author":"George","year":"2010","journal-title":"Blood."},{"issue":"22","key":"10.1016\/j.amjmed.2018.08.011_bib0009","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1056\/NEJM199811263392203","article-title":"Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura","volume":"339","author":"Tsai","year":"1998","journal-title":"N Engl J Med."},{"issue":"6855","key":"10.1016\/j.amjmed.2018.08.011_bib0010","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/35097008","article-title":"Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura","volume":"413","author":"Levy","year":"2001","journal-title":"Nature."},{"issue":"7","key":"10.1016\/j.amjmed.2018.08.011_bib0011","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1111\/j.1538-7836.2005.01436.x","article-title":"The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency","volume":"3","author":"Terrell","year":"2005","journal-title":"J Thromb Haemost."},{"issue":"5","key":"10.1016\/j.amjmed.2018.08.011_bib0012","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/DAD.0000000000000234","article-title":"Role of the skin biopsy in the diagnosis of atypical hemolytic uremic syndrome","volume":"37","author":"Magro","year":"2015","journal-title":"Am J Dermatopathol."},{"issue":"4","key":"10.1016\/j.amjmed.2018.08.011_bib0013","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/jch.12664","article-title":"Does anticomplement therapy have a role in the management of malignant hypertension?","volume":"18","author":"Tsai","year":"2016","journal-title":"J Clin Hypertens (Greenwich)."},{"issue":"5","key":"10.1016\/j.amjmed.2018.08.011_bib0014","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1097\/AOG.0000000000001340","article-title":"From gestational hypertension and preeclampsia to atypical hemolytic uremic syndrome","volume":"127","author":"Tsai","year":"2016","journal-title":"Obstet Gynecol."},{"key":"10.1016\/j.amjmed.2018.08.011_bib0015","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/295323","article-title":"Eculizumab therapy leads to rapid resolution of thrombocytopenia in atypical hemolytic uremic syndrome","volume":"2014","author":"Tsai","year":"2014","journal-title":"Adv Hematol."},{"issue":"24","key":"10.1016\/j.amjmed.2018.08.011_bib0016","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1182\/blood-2013-12-547067","article-title":"Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP","volume":"123","author":"Cataland","year":"2014","journal-title":"Blood."},{"issue":"23","key":"10.1016\/j.amjmed.2018.08.011_bib0017","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med."},{"issue":"6","key":"10.1016\/j.amjmed.2018.08.011_bib0018","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.kint.2016.12.009","article-title":"Patients with hypertension-associated thrombotic microangiopathy may present with complement abnormalities","volume":"91","author":"Timmermans","year":"2017","journal-title":"Kidney Int."},{"issue":"3","key":"10.1016\/j.amjmed.2018.08.011_bib0019","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/modpathol.2017.154","article-title":"Genetic testing of complement and coagulation pathways in patients with severe hypertension and renal microangiopathy","volume":"31","author":"Larsen","year":"2018","journal-title":"Mod Pathol"},{"issue":"12","key":"10.1016\/j.amjmed.2018.08.011_bib0020","doi-asserted-by":"crossref","first-page":"4542","DOI":"10.1182\/blood-2008-03-144691","article-title":"Factor H, membrane cofactor protein, and factor I mutations in patients with hemolysis, elevated liver enzymes, and low platelet count syndrome","volume":"112","author":"Fakhouri","year":"2008","journal-title":"Blood."},{"issue":"3","key":"10.1016\/j.amjmed.2018.08.011_bib0021","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001013","article-title":"Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort","volume":"8","author":"Salmon","year":"2011","journal-title":"PLoS Med."},{"issue":"2","key":"10.1016\/j.amjmed.2018.08.011_bib0022","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/jch.12243","article-title":"Mortality and cardiovascular risk in patients with a history of malignant hypertension: a case-control study","volume":"16","author":"Amraoui","year":"2014","journal-title":"J Clin Hypertens (Greenwich)."},{"issue":"212","key":"10.1016\/j.amjmed.2018.08.011_bib0023","first-page":"439","article-title":"Recovery in malignant hypertension presenting as acute renal failure","volume":"53","author":"Isles","year":"1984","journal-title":"Q J Med."},{"key":"10.1016\/j.amjmed.2018.08.011_bib0024","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1471-2369-13-71","article-title":"Long-term renal outcome in patients with malignant hypertension: a retrospective cohort study","volume":"13","author":"Amraoui","year":"2012","journal-title":"BMC Nephrol."}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934318307952?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934318307952?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T09:16:42Z","timestamp":1757582202000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934318307952"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S0002934318307952"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2018.08.011","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Atypical Hemolytic Uremic Syndrome: Beyond Hemolysis and Uremia","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2018.08.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2018.10.009","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}